Download PDF
Semin Thromb Hemost
DOI: 10.1055/a-2811-4911
Editorial

2026 Eberhard F Mammen Award Announcements: Part I—Most Popular Articles

Authors

  • Emmanuel J. Favaloro 

    1   Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR) and Research and Education Network (REN), Westmead Hospital, Westmead, Australia
    2   School of Dentistry and Medical Sciences, Faculty of Science and Health, Charles Sturt University, Wagga Wagga, Australia
    3   School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, Australia
Further Information
   Permissions and Reprints

Welcome to the latest of our Eberhard F Mammen award announcements. As noted in previous editorials ([Table 1]), Thieme, the publisher of Seminars in Thrombosis & Hemostasis (STH), has created the “Eberhard F Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard Mammen ([Fig. 1]), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009, under two categories, “Most Popular Article Awards and “Young Investigator Awards.” Accordingly, 2026 represents 18 years of award presentations ([Table 1]). Current details and conditions of the award can be summarized as:

Table 1

Previous editorials related to Eberhard F Mammen award announcements

1. Favaloro EJ. Welcome to a Special Issue of Seminars in Thrombosis and Hemostasis—The Closing Issue for 2008. Semin Thromb Hemost 2008;34:693–696

2. Favaloro EJ. A Tribute to Eberhard F. Mammen, M.D. (1930–2008). Semin Thromb Hemost 2008;34:703–708

3. Favaloro EJ. Welcome to the First Issue of Seminars in Thrombosis and Hemostasis for 2009. Semin Thromb Hemost 2009;35:1–2

4. Favaloro EJ. Winners of the Inaugural Eberhard F. Mammen Award for Most Popular Article. Semin Thromb Hemost 2009;35:587–590

5. Favaloro EJ. Editorial. 2009 Eberhard F. Mammen Young Investigator Award Winners. Semin Thromb Hemost 2010;36:469–470

6. Favaloro EJ. Winners of the 2010 Eberhard F. Mammen Award for Most Popular Article during 2008–2009. Semin Thromb Hemost. 2010;36(7):685–692

7. Favaloro EJ. 2011 Eberhard F. Mammen Award Announcements. Semin Thromb Hemost 2011;37(5):431–439

8. Favaloro EJ. 2012 Eberhard F. Mammen Award Announcements. Semin Thromb Hemost 2012;38:425–432

9. Favaloro EJ. 2013 Eberhard F. Mammen Award Announcements. Semin Thromb Hemost 39:567–574

10. Favaloro EJ. 2014 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles. Semin Thromb Hemost. 2014;40(4):407–12.

11. Favaloro EJ. 2014 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2014;40(7):718–723

12. Favaloro EJ. 2015 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles. Semin Thromb Hemost 2015;41(7):673–679

13. Favaloro EJ. 2015 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2015;41(8):809–815

14. Favaloro EJ. 2016 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles. Semin Thromb Hemost 2016;42(4):325–330

15. Favaloro EJ. 2016 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2017;43(3):235–241

16. Favaloro EJ. 2017 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles. Semin Thromb Hemost 2017;43(4):357–363

17. Favaloro EJ. 2017 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2018;44(2):81–88

18. Favaloro EJ. 2018 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles. Semin Thromb Hemost 2018;44(3):185–192

19. Favaloro EJ. 2018 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2019;45(2):123–129

20. Favaloro EJ. 2019 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles. Semin Thromb Hemost 2019;45(3):215–224

21. Favaloro EJ. 2019 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2020;46(2):105–113

22. Favaloro EJ. 2020 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles. Semin Thromb Hemost 2020;46(4):383–392

23. Favaloro EJ. 2020 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2021;47(3):229–237

24. Favaloro EJ. 2021 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles. Semin Thromb Hemost 2021;47(5):467–476

25. Favaloro EJ. 2021 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2022 Apr;48(3):265–273

26. Favaloro EJ. 2022 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles. Semin Thromb Hemost 2022 Jul;48(5):502–513

27. Favaloro EJ. 2023 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles. Semin Thromb Hemost 2023 Jul;49(5):417–426

28. Favaloro EJ. 2022 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost. 2023 Nov;49(8):775–782

29. Favaloro EJ. 2024 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles. Semin Thromb Hemost 2024 Oct;50(7):919–932

30. Favaloro EJ. 2023 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2024 Nov;50(8):1049–1057

31. Favaloro EJ. 2025 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles. Semin Thromb Hemost 2025 Jun;51(4):366–380

32. Favaloro EJ. 2024 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2025 July;51(5):481–490
Zoom
Fig. 1 Eberhard F. Mammen (1930–2008).

  • ➢ Most Popular Article Awards: Awarded to the authors of the most popular articles published in Seminars in Thrombosis & Hemostasis in the preceding 2 years as captured in the preceding year. The awards are determined by the Editor in Chief on the basis of user statistics from the publisher Thieme e-Journals. Prefaces, Errata, Letters to the Editor, Editorials, short Commentaries, and previous award-winning articles are excluded from further consideration of these awards, which currently comprise two categories—one for “Free Access” articles, and another for a “General Category.” There are two major cash prizes of US$1,000 for each category. In addition, winners of the “General Category” awards are granted “Free Access” status for these articles thereafter.

  • ➢ Young Investigator Awards: Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr Mammen. Up to six cash prizes of US$1,000 in any year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other paper related to the topic of their presentation (or as otherwise agreed) for publication in Seminars in Thrombosis & Hemostasis. Previous award winners are excluded from a second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by a vote of the Senior Editors of STH. Any potential conflicts of interest are managed by first identifying these, and then excluding those with potential conflicts from voting. Finally, given historical COVID-19 concerns, some meetings are still held as virtual or hybrid meetings, and accordingly, these meeting presentations can also be considered for the award.

Further details of the awards and the award winners are posted online (https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077), and previous award winner announcements are also available in print (see [Table 1]).

It is therefore with great pleasure that we would like to announce the latest winners of the 2026 Eberhard F Mammen awards for the most popular articles from Seminars in Thrombosis & Hemostasis, as downloaded in 2025 and as published in the period of 2024 and 2025 inclusive.

Authors' Contributions

E.J.F.: conceptualization, formal analysis, methodology, writing—original draft, writing—review and editing.




Publication History

Received: 01 February 2026

Accepted: 10 February 2026

Article published online:
26 February 2026

© 2026. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 El-Sherbini AH, Coroneos S, Zidan A, Othman M. Machine learning as a diagnostic and prognostic tool for predicting thrombosis in cancer patients: a systematic review. Semin Thromb Hemost 2024; 50 (06) 809-816
    Search in Google Scholar
  • 2 Moore GW. Thrombophilia screening: not so straightforward. Semin Thromb Hemost 2024; 50 (08) 1131-1152
    Search in Google Scholar
  • 3 Talasaz AH, McGonagle B, HajiQasemi M. et al. Pharmacokinetic and pharmacodynamic interactions between food or herbal products and oral anticoagulants: evidence review, practical recommendations, and knowledge gaps. Semin Thromb Hemost 2025; 51 (05) 560-571
    Search in Google Scholar
  • 4 Favaloro EJ. The role of the von Willebrand factor collagen-binding assay (VWF:CB) in the diagnosis and treatment of von Willebrand disease (VWD) and way beyond: a comprehensive 36-year history. Semin Thromb Hemost 2024; 50 (01) 43-80
    Search in Google Scholar
  • 5 Gosselin RC, Castellone D, Dorgalaleh A. et al. International Council for Standardization in Haematology guidance for new lot verification of coagulation reagents, calibrators, and controls. Semin Thromb Hemost 2024; 50 (08) 1091-1102
    Search in Google Scholar
  • 6 Yong BSJ, Ling RR, Li R. et al. Pharmacotherapy for venous thromboprophylaxis following total hip or knee arthroplasty: a systematic review and network meta-analysis. Semin Thromb Hemost 2025; 51 (03) 290-300
    Search in Google Scholar
  • 7 Perrone S, Raso S, Napolitano M. Clinical, laboratory, and molecular characteristics of inherited vitamin K-dependent coagulation factors deficiency. Semin Thromb Hemost 2025; 51 (02) 170-179
    Search in Google Scholar
  • 8 Franchini M, Focosi D, Pezzo MP, Mannucci PM. Catastrophic thrombosis: a narrative review. Semin Thromb Hemost 2025; 51 (03) 312-321
    Search in Google Scholar
  • 9 Spiezia L, Campello E, Tormene D, Simioni P. Venous thromboembolism in children: the rivaroxaban experience. Semin Thromb Hemost 2024; 50 (06) 866-872
    Search in Google Scholar
  • 10 Aguirre Del-Pino R, Monahan RC, Huizinga TWJ, Eikenboom J, Steup-Beekman GM. Risk factors for antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost 2024; 50 (06) 817-828
    Search in Google Scholar
  • 11 Pretorius E, Kell DB. A perspective on how fibrinaloid microclots and platelet pathology may be applied in clinical investigations. Semin Thromb Hemost 2024; 50 (04) 537-551
    Search in Google Scholar
  • 12 Hellfritzsch M, Henriksen JN, Holt MI, Grove EL. Drug-drug interactions in the treatment of cancer-associated venous thromboembolism with direct oral anticoagulants. Semin Thromb Hemost 2024; 50 (03) 489-498
    Search in Google Scholar
  • 13 Al-Ghafry M, Abou-Ismail MY, Acharya SS. Inherited disorders of the fibrinolytic pathway: pathogenic phenotypes and diagnostic considerations of extremely rare disorders. Semin Thromb Hemost 2025; 51 (02) 227-235
    Search in Google Scholar
  • 14 Warkentin TE. Limb ischemic necrosis secondary to microvascular thrombosis: a brief historical review. Semin Thromb Hemost 2024; 50 (05) 760-772
    Search in Google Scholar
  • 15 Martens ESL, Huisman MV, van Mens TE, Klok FA. The history of diagnosing venous thromboembolism. Semin Thromb Hemost 2024; 50 (05) 739-750
    Search in Google Scholar
  • 16 Dolan G, Fijnvandraat K, Lenting PJ, Catarino C, Lavin M. Factor Think Tank. Nonsevere hemophilia: the need for a renewed focus and improved outcomes. Semin Thromb Hemost 2025; 51 (01) 58-67
    Search in Google Scholar
  • 17 Barcellona D, Marongiu F, Grandone E. Contraceptives and thrombosis: an intertwined revolutionary road. Semin Thromb Hemost 2024; 50 (01) 91-95
    Search in Google Scholar
  • 18 Petersen RS, Fijen LM, Levi M, Cohn DM. Hereditary angioedema: the clinical picture of excessive contact activation. Semin Thromb Hemost 2024; 50 (07) 978-988
    Search in Google Scholar
  • 19 Favaloro EJ. Evolution of hemostasis testing: a personal reflection covering over 40 years of history. Semin Thromb Hemost 2024; 50 (01) 8-25
    Search in Google Scholar
  • 20 Khoury R, Chapman J. Inflammation and coagulation in neurologic and psychiatric disorders. Semin Thromb Hemost 2025; 51 (04) 465-470
    Search in Google Scholar
  • 21 Bavinck AP, Heerde WV, Schols SEM. Point-of-care testing in patients with hereditary disorders of primary hemostasis: a narrative review. Semin Thromb Hemost 2025; 51 (05) 541-559
    Search in Google Scholar
  • 22 Bissola AL, Zhang Y, Cranstone M. et al. Evaluating diagnostic algorithms for heparin-induced thrombocytopenia using two combined automated rapid immunoassays. Semin Thromb Hemost 2024; 50 (08) 1123-1130
    Search in Google Scholar
  • 23 Trujillo-Santos J, Demelo-Rodríguez P, Bravo de Laguna-Taboada A. et al; Working Group on for the Consensus on Venous Stenting. Optimizing venous stenting: consensus recommendations for enhanced management of lower extremity deep vein thrombosis. Semin Thromb Hemost 2024; 50 (06) 883-893
    Search in Google Scholar
  • 24 Ichinose A, Osaki T, Souri M. Diagnosis and treatment of autoimmune acquired coagulation factor deficiencies: an evidence-based review of Japanese practice. Semin Thromb Hemost 2025; 51 (05) 491-505
    Search in Google Scholar
  • 25 Varjú I, Tanka-Salamon A, Kolev K. Neutrophil extracellular traps: at the interface of thrombosis and comorbidities. Semin Thromb Hemost 2025; 51 (07) 724-735
    Search in Google Scholar
  • 26 Davidson S, Gomez K. Laboratory and molecular diagnosis of factor XI deficiency. Semin Thromb Hemost 2025; 51 (02) 145-154
    Search in Google Scholar
  • 27 Arachchillage DJ, Kitchen S. Pleiotropic effects of heparin and its monitoring in the clinical practice. Semin Thromb Hemost 2024; 50 (08) 1153-1162
    Search in Google Scholar
  • 28 Chen Q, Anijs RJS, Verlaan JPL, Scheres LJJ, Klok FA, Cannegieter SC. Novel antidiabetic drugs and risk of venous thromboembolism: a literature review. Semin Thromb Hemost 2025; 51 (07) 756-767
    Search in Google Scholar
  • 29 Steiner D, Nopp S, Hoberstorfer T. et al. Hemostatic and inflammatory biomarkers are associated with functional limitations after venous thromboembolism: a prospective cohort study. Semin Thromb Hemost 2025; 51 (07) 809-817
    Search in Google Scholar
  • 30 Mancuso ME. Factor replacement treatment for hemophilia A: achievements and perspectives. Semin Thromb Hemost 2025; 51 (01) 18-22
    Search in Google Scholar
  • 31 Jiménez-Yuste V. Non-factor therapies for hemophilia: achievements and perspectives. Semin Thromb Hemost 2025; 51 (01) 23-27
    Search in Google Scholar
  • 32 Bala NS, Thornburg CD. Gene therapy in hemophilia A: achievements, challenges, and perspectives. Semin Thromb Hemost 2025; 51 (01) 28-40
    Search in Google Scholar
  • 33 Giuffrida AC, Siboni SM, Baronciani L, Poli G, Gandini G, Peyvandi F. Emicizumab in type 3 von Willebrand disease: report of a case with an alloantibody and literature Review. Semin Thromb Hemost 2025; 51 (01) 73-80
    Search in Google Scholar
  • 34 Coppola A, Zani M, Quintavalle G, Focosi D, Franchini M. The evolution of hemophilia pharmacological treatments and therapeutic targets at the turn of the third millennium. Semin Thromb Hemost 2025; 51 (01) 10-17
    Search in Google Scholar
  • 35 Cerrone A, Buscarini E, Berté R. et al. Hereditary hemorrhagic telangiectasia: on the brink of a new treatment era?. Semin Thromb Hemost 2025; 51 (01) 91-97
    Search in Google Scholar
  • 36 Franchini M, Focosi D. Innovative therapies for acquired hemophilia A. Semin Thromb Hemost 2025; 51 (01) 68-72
    Search in Google Scholar
  • 37 Nurden AT, Nurden P. Glanzmann thrombasthenia 10 years later: progress made and future directions. Semin Thromb Hemost 2025; 51 (02) 196-208
    Search in Google Scholar
  • 38 Kaya Z. Bernard-Soulier syndrome: a review of epidemiology, molecular pathology, clinical features, laboratory diagnosis, and therapeutic management. Semin Thromb Hemost 2025; 51 (02) 209-218
    Search in Google Scholar
  • 39 Gyldenholm T, Hvas AM, Christensen TD, Larsen JB. Thrombin generation markers as predictors of cancer-associated venous thromboembolism: a systematic review. Semin Thromb Hemost 2024; 50 (03) 384-401
    Search in Google Scholar
  • 40 Bernardi F, Mariani G. Clinical, laboratory, and molecular aspects of factor VII deficiency. Semin Thromb Hemost 2025; 51 (02) 128-137
    Search in Google Scholar
  • 41 Franchini M, Focosi D. Clinical, laboratory, and molecular aspects of factor V deficiency. Semin Thromb Hemost 2025; 51 (02) 111-115
    Search in Google Scholar
  • 42 Willems RAL, Biesmans C, Campello E. et al. Cellular components contributing to the development of venous thrombosis in patients with pancreatic cancer. Semin Thromb Hemost 2024; 50 (03) 429-442
    Search in Google Scholar
  • 43 Menegatti M, Peyvandi F. Clinical, laboratory aspects and management of factor X deficiency. Semin Thromb Hemost 2025; 51 (02) 138-144
    Search in Google Scholar
  • 44 Mansueto MF, Bigi S, Follino M, Lupi A, Coppola A. Patient perspective on disease burden and gene therapy for hemophilia A and B: the “Haemvolution for Patients” Italian survey. Semin Thromb Hemost 2025; 51 (01) 49-57
    Search in Google Scholar
  • 45 Bendas G, Schlesinger M. The role of CD36/GPIV in platelet biology. Semin Thromb Hemost 2024; 50 (02) 224-235
    Search in Google Scholar
  • 46 Leerson J, Tulloh A, Lopez FT, Gregory S, Buscher H, Rosengarten G. Detecting oxygenator thrombosis in ECMO: a review of current techniques and an exploration of future directions. Semin Thromb Hemost 2024; 50 (02) 253-270
    Search in Google Scholar
  • 47 Goel A, Tathireddy H, Wang SH. et al. Targeting the contact pathway of coagulation for the prevention and management of medical device-associated thrombosis. Semin Thromb Hemost 2024; 50 (07) 989-997
    Search in Google Scholar
  • 48 Papadakis E, Gavriilaki E, Kotsiou N, Tufano A, Brenner B. Fright of long-haul flights: focus on travel-associated thrombosis. Semin Thromb Hemost 2025; 51 (04) 438-447
    Search in Google Scholar
  • 49 Casini A, Moerloose P, Neerman-Arbez M. Clinical, laboratory, and molecular aspects of congenital fibrinogen disorders. Semin Thromb Hemost 2025; 51 (02) 103-110
    Search in Google Scholar
  • 50 Dorgalaleh A, Jozdani S, Zadeh MK. Factor XIII deficiency: laboratory, molecular, and clinical aspects. Semin Thromb Hemost 2025; 51 (02) 155-169
    Search in Google Scholar
  • 51 Gyawali P, Lillicrap TP, Esperon CG, Bhattarai A, Bivard A, Spratt N. Whole blood viscosity and cerebral blood flow in acute ischemic stroke. Semin Thromb Hemost 2024; 50 (04) 580-591
    Search in Google Scholar
  • 52 Fu A, Kazmirchuk TDD, Bradbury-Jost C, Golshani A, Othman M. Platelet-type von Willebrand disease: complex pathophysiology and insights on novel therapeutic and diagnostic strategies. Semin Thromb Hemost 2025; 51 (02) 219-226
    Search in Google Scholar
  • 53 Castaman G, Miesbach W. Gene therapy for hemophilia B: achievements, open issues, and perspectives. Semin Thromb Hemost 2025; 51 (01) 41-48
    Search in Google Scholar
  • 54 Kiskaddon AL, Witt DM, Betensky M. et al. Anticoagulants in children with renal impairment: a narrative review. Semin Thromb Hemost 2025; 51 (07) 776-787
    Search in Google Scholar
  • 55 Capece GE, Luyendyk JP, Poole LG. Fibrinolysis-mediated pathways in acute liver injury. Semin Thromb Hemost 2024; 50 (04) 638-647
    Search in Google Scholar
  • 56 von Känel R. Stress-induced hypercoagulability: insights from epidemiological and mechanistic studies, and clinical integration. Semin Thromb Hemost 2025; 51 (04) 381-400
    Search in Google Scholar
  • 57 Undas A. Laboratory testing for fibrinogen disorders: from routine investigations to research studies. Semin Thromb Hemost 2025; 51 (06) 651-659
    Search in Google Scholar
  • 58 Federici AB. Current diagnosis of von Willebrand disease in Italy: 3 years following the release of the international guidelines. Semin Thromb Hemost 2025; 51 (01) 81-90
    Search in Google Scholar
  • 59 Tavasoli B, Zangooie A, Safdari SM. et al. Correlation between phenotype and coagulation factor activity level in rare bleeding disorders: a systematic review. Semin Thromb Hemost 2025; 51 (02) 180-195
    Search in Google Scholar
  • 60 Kiskaddon AL, Goldenberg NA, Fierstein JL, Miller A, Quintessenza JA, Kartha VM. Dosing, monitoring, blood product utilization, and thromboembolic complications of four-factor prothrombin complex concentrate as part of an institutional protocol in pediatric cardiac surgery: a retrospective cohort study. Semin Thromb Hemost 2024; 50 (06) 873-882
    Search in Google Scholar
  • 61 Dorgalaleh A, Othman M. Precision medicine in rare bleeding disorders. Semin Thromb Hemost 2025; 51 (02) 99-102
    Search in Google Scholar
  • 62 Coppola A, Franchini M. Advances in the management of hemophilia and bleeding disorders: achievements and perspectives. Semin Thromb Hemost 2025; 51 (01) 2-4
    Search in Google Scholar
  • 63 Schulman S. Recent advances in thrombosis and hemostasis—part X. Semin Thromb Hemost 2024; 50 (06) 807-808
    Search in Google Scholar
  • 64 Schulman S. Recent advances in thrombosis and hemostasis—part XII. Semin Thromb Hemost 2025; 51 (07) 721-723
    Search in Google Scholar
  • 65 Smock KJ, Moffat KA. Laboratory diagnostics for thrombosis and hemostasis testing—part III. Semin Thromb Hemost 2024; 50 (08) 1047-1048
    Search in Google Scholar